ADAR1 Capital Management »

Akebia Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Akebia Therapeutics (AKBA) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Akebia Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Akebia Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Akebia Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $18k 9.7k 1.83

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Akebia Therapeutics

BlackRock
BlackRock
Vanguard Group
Satter Management
Geode Capital Management
Renaissance Technologies
State Street Corporation
Jacobs Levy Equity Management
Qube Research & Technologies
Northern Trust
Connor, Clark & Lunn Investment Management
Federated Investors
Morgan Stanley
Charles Schwab Investment Management
Bank of New York Mellon

View all funds holding Akebia Therapeutics